Monotherapy trials: presurgical studies.
Presurgical evaluation of patients with refractory partial seizures provides a unique opportunity to perform a placebo-controlled, monotherapy trial. Some patients undergoing presurgical evaluations must have all of their antiepileptic drugs (AEDs) tapered in order to induce seizures and therefore such patients are possible candidates for a placebo-controlled monotherapy trial. Often, EEG monitoring is continued throughout the trial period, thus patients either receiving placebo or whose seizures do not completely respond to the active drug are still evaluated to determine whether or not surgery is feasible, supporting the validity of a trial in this setting. In addition, all patients are, in general, eligible to receive the study drug after the blinded period of the trial, and can therefore be assured of the possible therapeutic benefits of the study. Presurgical inpatients studies have been carried out using felbamate, gabapentin and oxcarbazepine. All patients randomised in these trials were refractory to previous treatment and the studies themselves were short-term and placebo-controlled. These presurgical studies are designed to elucidate AED activity and show statistically significant differences between active and control treatments during short-term therapy, and are therefore of use in fulfilling regulatory requirements. However, these measures of efficacy are distinctly different from those determined during chronic treatment and are therefore not necessarily predictive of clinical usefulness.
Pledger
G
G
RW Johnson Pharmaceutical Research Institute, 929 Route 202, South Raritan, NJ 9202, USA. gpledger@prius.jnj.com
D000927:Anticonvulsants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D012107:Research Design
D000927:Anticonvulsants